These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 21995569)

  • 21. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.
    Melki MT; Saïdi H; Dufour A; Olivo-Marin JC; Gougeon ML
    PLoS Pathog; 2010 Apr; 6(4):e1000862. PubMed ID: 20419158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral inhibitors of NKG2D ligands for tumor surveillance.
    Chávez-Blanco A; Chacón-Salinas R; Dominguez-Gomez G; Gonzalez-Fierro A; Perez-Cardenas E; Taja-Chayeb L; Trejo-Becerril C; Duenas-Gonzalez A
    Expert Opin Ther Targets; 2016 Nov; 20(11):1375-1387. PubMed ID: 27322108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective.
    Mahmood S; Upreti D; Sow I; Amari A; Nandagopal S; Kung SK
    Immunotherapy; 2015; 7(3):301-8. PubMed ID: 25804481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural killer cells: In health and disease.
    Mandal A; Viswanathan C
    Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):47-55. PubMed ID: 25571788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of natural killer cells in cancer therapy and transplantation.
    Knorr DA; Bachanova V; Verneris MR; Miller JS
    Semin Immunol; 2014 Apr; 26(2):161-72. PubMed ID: 24618042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Natural Killer-Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy.
    Peterson EE; Barry KC
    Front Immunol; 2020; 11():621254. PubMed ID: 33613552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
    Terme M; Ullrich E; Delahaye NF; Chaput N; Zitvogel L
    Nat Immunol; 2008 May; 9(5):486-94. PubMed ID: 18425105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
    Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
    Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
    Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
    Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer cell-mediated immunosurveillance of human cancer.
    Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
    Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement-Opsonized HIV-1 Alters Cross Talk Between Dendritic Cells and Natural Killer (NK) Cells to Inhibit NK Killing and to Upregulate PD-1, CXCR3, and CCR4 on T Cells.
    Ellegård R; Khalid M; Svanberg C; Holgersson H; Thorén Y; Wittgren MK; Hinkula J; Nyström S; Shankar EM; Larsson M
    Front Immunol; 2018; 9():899. PubMed ID: 29760706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing NK Cell Memory for Cancer Immunotherapy.
    Fehniger TA; Cooper MA
    Trends Immunol; 2016 Dec; 37(12):877-888. PubMed ID: 27773685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
    Zhuang X; Long EO
    Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy.
    Wu F; Xie M; Hun M; She Z; Li C; Luo S; Chen X; Wan W; Wen C; Tian J
    Front Immunol; 2021; 12():658698. PubMed ID: 34093547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
    Front Immunol; 2021; 12():791206. PubMed ID: 34804076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.
    Noh JY; Yoon SR; Kim TD; Choi I; Jung H
    J Immunol Res; 2020; 2020():2045860. PubMed ID: 32377528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy.
    Yang G; Kong Q; Wang G; Jin H; Zhou L; Yu D; Niu C; Han W; Li W; Cui J
    Cancer Biother Radiopharm; 2014 Dec; 29(10):428-34. PubMed ID: 25402754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.